historically designed to focus on a single gene target. Modulation of single target may unknowingly effect or interfere with other pathways. Bionaut's Sentinel® Pathway Reporter System can greatly increase the chances of a positive clinical outcome for a new drug candidate by correlating pathway-specific interference directly with disease modulation in living human cells. Bionaut has applied the highly predictive capabilities of its Sentinel system to build a pipeline of its own drug candidates in the areas of cancer and inflammation.